hospitals
Fourth Circuit sends 340B drug-discount fight to full court
The full court will rehear a West Virginia dispute over how the federal 340B program applies to hospitals and clinics. The case now returns to oral argument, with drugmakers and state officials still split over how far the savings can go.
The Fourth Circuit has agreed to rehear a West Virginia case over the federal 340B drug-discount program. The fight centers on how the program reaches hospitals and clinics, and how much those lower prices can help patients.
- The Fourth Circuit will rehear a West Virginia 340B dispute.
- 340B lets certain hospitals and clinics buy medicines at reduced prices.
- The case could affect how far those savings reach patients.
- The earlier panel ruling is no longer the final word.
- West Virginia hospitals and clinics are back in the middle of a fight over 340B, the federal drug-discount program that lets eligible providers buy medicines at reduced prices
West Virginia hospitals and clinics are back in the middle of a fight over 340B, the federal drug-discount program that lets eligible providers buy medicines at reduced prices. On May 28, the Fourth Circuit agreed to rehear the case en banc, taking another look at a dispute that pits Pharmaceutical Research and Manufacturers of America against West Virginia Attorney General John B. McCuskey and other state officials.
The underlying question is how the 340B program reaches hospitals and clinics, and how far those savings stretch for patients.
Where the savings land
The case sits at the point where drug pricing meets hospital budgets and access to care. For providers that rely on 340B, the program can affect how much room they have to keep prescriptions within reach.
For now, the full court has pulled the dispute back into play. The panel ruling is no longer the last word.